Clinical trial NCT01577628: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Official title: Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Atopic Dermatitis
Eczema
Asthma
Food Allergies
Allergic Rhinitis
Keywords: Dermatitis
Eczema
Skin diseases
Skin barrier
Prevention
Infant
Moisturizer
Emollient
Asthma
Food allergy
Allergic rhinitis
Lead sponsor: Cosmetique Active International
Sponsor class: INDUSTRY
Collaborators: name: Innovaderm Research Inc.
First posted: 2012-04-16
Enrollment: 2
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis. Although generally accepted and widely used for secondary prevention, emollients have not been studied as a primary prevention strategy. Strategies previously studied for the prevention of atopic dermatitis include maternal and child's dietary manipulations, allergens avoidance, delay of food introduction, exclusive breastfeeding and probiotic supplementation. Despite years of research, none of those strategies yielded to strong evidence of a protective effect. There is therefore a need to explore novel strategies.

There is a need to compare the cumulative incidence rate of atopic dermatitis in newborns using a standard bathing and moisturizing routine with a good moisturizer to a non interventional group.

This 2-year study will recruit approximately four hundred and sixty (460) pregnant women with a first degree relative of the child to be born who currently has (or previously had) a diagnosis of atopic dermatitis in order to study approximately 200 eligible newborns in each of the two study groups at the beginning of the study.

Pregnant women will be randomized (1:1) to either daily use of the moisturizer Lipikar Balm AP (applied to their infant) starting from birth (Group 1) immediately after bathing or to no intervention (Group 2).

Detailed description: To be eligible, pregnant women must be at least 16 weeks pregnant. Expecting mothers (or the father of the infant to be born) or related sibling of the child to be born must meet or previously have met criteria for atopic dermatitis. In addition, one of the parents or sibling of the child to be born must suffer from allergic rhinitis or asthma.

Pregnant women will be randomized at screening and their infant will be seen at 1 month, 6 months, 12 months (1 year) and 24 months (2 years) after birth.

Women randomized to group 1 will be requested to use the same body cleanser (Lipikar Syndet) and to apply Lipikar Balm AP to their child once daily immediately after bathing on a well blotted skin (within 3 minutes of bathing) to the entire body (including the face) from birth, while women randomized to group 2 will be in a non-interventional control group.

The presence of atopic dermatitis (using Hanifin's criteria(1)) and study products use will be assessed at 1 month, 6 months, 12 months and 24 months after birth. A buccal smear will be sampled from all infants at 1 month after birth for the genotyping of filaggrin (FLG) gene.

In addition, adverse events evaluation and parent questioning on infants development of food allergies and asthma will be performed at 1 month, 3 months (telephone visit), 6 months, 12 months and 24 months after birth. Infants will be followed for a total of two years after birth.

Lipikar Balm AP is a commonly used cosmetic moisturizer commercially available in many countries including Canada. This moisturizer is recommended for extreme dryness and atopy-prone skin in babies, children and adults. It contains shea butter, paraffin, waxes and vegetable oils. The high content in shea butter and the fraction chosen showed a greater expression of constitutive ceramids forming the barrier function of the skin (data on file at La Roche-Posay).

Eligibility criteria: Inclusion Criteria:

* Women 18 years of age or older at the time of consent
* At least 16 weeks pregnant
* Women with a high risk of having a child with atopic dermatitis defined as having one parent or related sibling of the child to be born who currently (or previously) suffers from atopic dermatitis and who also suffers from asthma or allergic rhinitis
* Be willing to use the body cleanser Lipikar Syndet and to apply Lipikar Balm AP (if randomized to group 1) every day from birth for 2 years
* Capable of giving informed consent and the consent must be obtained prior to any study related procedures

Exclusion Criteria:

* Preterm birth defined as birth before 37 weeks of gestation
* Major congenital anomaly at birth
* Presence of significant dermatitis at birth
* Any medical problem at birth that would prevent the daily use of Lipikar Syndet and/or Lipikar Balm AP (regardless of the group the subject was randomized to) or would prevent evaluation of the skin for the presence of atopic dermatitis

Primary outcomes:
measure: Proportion of Infants Who Develop Atopic Dermatitis
timeFrame: 2 years
Secondary outcomes:
measure: Proportion of Infants Who Develop Asthma
timeFrame: 2 years
measure: Proportion of Infants Who Develop a Food Allergy
timeFrame: 2 years
measure: Influence of the Presence of Mutation in the Filaggrin Gene on the Proportion of Infants Who Develop Atopic Dermatitis
timeFrame: 2 years
measure: Influence of the Presence of Mutation in the Filaggrin Gene on the Proportion of Infants Who Develop Asthma
timeFrame: 2 years
measure: Influence of the Presence of Mutation in the Filaggrin Gene on the Proportion of Infants Who Develop a Food Allergy
timeFrame: 2 years
measure: Time of Onset of Asthma in Infants
timeFrame: 2 years
measure: Time of Onset of Food Allergy in Infants
timeFrame: 2 years
measure: Adverse Events (AEs) Collection
timeFrame: 2 years
measure: Time of Onset of Atopic Dermatitis
timeFrame: 2 years
Other outcomes:
Locations:
city: Canton
country: United States
facility: Hamzavi Dermatology/Dermatology Specialists of Canton
state: Michigan
city: Fort Gratiot
country: United States
facility: Hamzavi Dermatology
state: Michigan
city: Markham
country: Canada
facility: Lynderm Research
state: Ontario
city: Windsor
country: Canada
facility: Windsor Clinical Research
state: Ontario
Study officials:
affiliation: Innovaderm Research
name: Robert Bissonnette, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: